TFR Capital LLC. Acquires 781 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

TFR Capital LLC. increased its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 12.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,011 shares of the medical equipment provider's stock after purchasing an additional 781 shares during the period. Intuitive Surgical makes up 1.4% of TFR Capital LLC.'s investment portfolio, making the stock its 17th biggest holding. TFR Capital LLC.'s holdings in Intuitive Surgical were worth $3,472,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Brighton Jones LLC boosted its holdings in Intuitive Surgical by 24.9% during the fourth quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider's stock valued at $1,916,000 after acquiring an additional 731 shares during the period. Bank Pictet & Cie Europe AG raised its position in Intuitive Surgical by 0.5% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 190,969 shares of the medical equipment provider's stock worth $99,678,000 after purchasing an additional 883 shares in the last quarter. Proficio Capital Partners LLC raised its position in Intuitive Surgical by 70.9% in the fourth quarter. Proficio Capital Partners LLC now owns 1,820 shares of the medical equipment provider's stock worth $950,000 after purchasing an additional 755 shares in the last quarter. Moors & Cabot Inc. increased its holdings in shares of Intuitive Surgical by 8.4% during the fourth quarter. Moors & Cabot Inc. now owns 1,256 shares of the medical equipment provider's stock worth $656,000 after buying an additional 97 shares in the last quarter. Finally, Commonwealth Equity Services LLC increased its holdings in shares of Intuitive Surgical by 5.9% during the fourth quarter. Commonwealth Equity Services LLC now owns 74,140 shares of the medical equipment provider's stock worth $38,698,000 after buying an additional 4,145 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently commented on ISRG. Barclays decreased their price target on shares of Intuitive Surgical from $684.00 to $635.00 and set an "overweight" rating on the stock in a research note on Thursday, April 24th. Erste Group Bank raised shares of Intuitive Surgical from a "hold" rating to a "buy" rating in a research note on Thursday, June 5th. Evercore ISI increased their price target on shares of Intuitive Surgical from $470.00 to $550.00 and gave the company an "in-line" rating in a research note on Tuesday, July 8th. Truist Financial decreased their price target on shares of Intuitive Surgical from $605.00 to $590.00 and set a "buy" rating on the stock in a research note on Wednesday, April 23rd. Finally, Royal Bank Of Canada decreased their price target on shares of Intuitive Surgical from $630.00 to $605.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 23rd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have given a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $592.86.

Insider Activity at Intuitive Surgical

In related news, EVP Gary Loeb sold 1,700 shares of the firm's stock in a transaction on Friday, April 25th. The shares were sold at an average price of $513.18, for a total transaction of $872,406.00. Following the sale, the executive vice president directly owned 2,245 shares in the company, valued at $1,152,089.10. This trade represents a 43.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Mark Brosius sold 216 shares of the firm's stock in a transaction on Friday, June 6th. The stock was sold at an average price of $563.11, for a total transaction of $121,631.76. Following the sale, the senior vice president owned 907 shares in the company, valued at approximately $510,740.77. The trade was a 19.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 4,998 shares of company stock valued at $2,611,577. Insiders own 0.70% of the company's stock.

Intuitive Surgical Stock Down 0.4%

Intuitive Surgical stock traded down $1.91 during mid-day trading on Tuesday, hitting $514.54. 774,727 shares of the company's stock were exchanged, compared to its average volume of 1,680,210. The firm has a market capitalization of $184.42 billion, a P/E ratio of 75.36, a PEG ratio of 5.43 and a beta of 1.64. Intuitive Surgical, Inc. has a fifty-two week low of $413.82 and a fifty-two week high of $616.00. The company's 50 day simple moving average is $537.54 and its 200-day simple moving average is $536.54.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its quarterly earnings data on Tuesday, April 22nd. The medical equipment provider reported $1.81 EPS for the quarter, topping the consensus estimate of $1.71 by $0.10. Intuitive Surgical had a return on equity of 14.43% and a net margin of 28.41%. The business had revenue of $2.25 billion for the quarter, compared to the consensus estimate of $2.19 billion. During the same quarter last year, the business posted $1.50 EPS. Research analysts expect that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.